Lumos Diagnostics Holdings Ltd (LDX) - Total Liabilities
Based on the latest financial reports, Lumos Diagnostics Holdings Ltd (LDX) has total liabilities worth AU$14.65 Million AUD as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Lumos Diagnostics Holdings Ltd - Total Liabilities Trend (2017–2024)
This chart illustrates how Lumos Diagnostics Holdings Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Lumos Diagnostics Holdings Ltd Competitors by Total Liabilities
The table below lists competitors of Lumos Diagnostics Holdings Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Majestic Gold Corp.
V:MJS
|
Canada | CA$89.99 Million |
|
Bioxyne Ltd
AU:BXN
|
Australia | AU$14.45 Million |
|
Martin Midstream Partners LP
NASDAQ:MMLP
|
USA | $592.86 Million |
|
Jeld-Wen Holding Inc
NYSE:JELD
|
USA | $2.06 Billion |
|
Bulten AB
ST:BULTEN
|
Sweden | Skr2.68 Billion |
|
TOPMATERIAL LTD
KQ:360070
|
Korea | ₩72.50 Billion |
|
Turbogen Chp
TA:TURB
|
Israel | ILA28.87 Million |
Liability Composition Analysis (2017–2024)
This chart breaks down Lumos Diagnostics Holdings Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.74 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.22 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.38 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.70 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Lumos Diagnostics Holdings Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Lumos Diagnostics Holdings Ltd (2017–2024)
The table below shows the annual total liabilities of Lumos Diagnostics Holdings Ltd from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | AU$14.65 Million | -25.72% |
| 2023-12-31 | AU$19.73 Million | +23.92% |
| 2022-12-31 | AU$15.92 Million | -16.45% |
| 2021-12-31 | AU$19.05 Million | -52.01% |
| 2020-12-31 | AU$39.71 Million | +388.81% |
| 2019-12-31 | AU$8.12 Million | -40.89% |
| 2018-12-31 | AU$13.74 Million | +132.44% |
| 2017-12-31 | AU$5.91 Million | -- |
About Lumos Diagnostics Holdings Ltd
Lumos Diagnostics Holdings Limited develops, manufactures, and commercializes point-of-care diagnostic products for diagnosis and management of infectious diseases in the United States. The company's products include FebriDx, a point-of-care diagnostic test for detecting and differentiating viral and bacterial respiratory infections; and ViraDx, a three-in-one point-of-care test for influenza A, … Read more